NFKB1 and neoplasm: Mechanistic insights from genetically engineered mouse models and clinical samples highlight the ability of NRF2 signaling to inhibit cell death pathways, impair STING and NF-kB signaling, and drive an immunosuppressive microenvironment which is favorable to tumor progression.